Effects of Single Dose Citalopram and Reboxetine on Urethral and Anal Closure Function on Healthy Female Subjects
Status:
Completed
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
This study will investigate if citalopram, a selective serotonin reuptake inhibitor, is
reducing the opening pressure of the urethra and possibly causing or worsening stress urinary
incontinence. Reboxetine, a norepinephrine reuptake inhibitor, is known to increase urethral
opening pressure through actions on adrenoceptors in Onuf´s nucleus and will act as an active
control.
Furthermore, this study is performed to explore the effects of reboxetine and citalopram on
the opening pressure of the anal canal.